3-{(3aS,4R,8R,8aS)-4,8-Dibenzyl-2,2-dimethyl-6-oxo-7-[1-(2-trimethylsilanyl-ethoxymethyl)-1H-indazol-5-ylmethyl]-hexahydro-1,3-dioxa-5,7-diaza-azulen-5-ylmethyl}-benzoic acid | 209804-80-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 英文名称: 3-{(3aS,4R,8R,8aS)-4,8-Dibenzyl-2,2-dimethyl-6-oxo-7-[1-(2-trimethylsilanyl-ethoxymethyl)-1H-indazol-5-ylmethyl]-hexahydro-1,3-dioxa-5,7-diaza-azulen-5-ylmethyl}-benzoic acid
• 英文别名: 3-[[(3aS,4R,8R,8aS)-4,8-dibenzyl-2,2-dimethyl-6-oxo-5-[[1-(2-trimethylsilylethoxymethyl)indazol-5-yl]methyl]-3a,4,8,8a-tetrahydro-[1,3]dioxolo[4,5-e][1,3]diazepin-7-yl]methyl]benzoic acid
• CAS: 209804-80-8
• 化学式: C₄₄H₅₂N₄O₆Si
• 分子量: 761.006
• InChiKey: QUNPHUPAKLJJAL-BHTPUMDESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.23
• 重原子数：
  55
• 可旋转键数：
  14
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  106
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  3-{(3aS,4R,8R,8aS)-4,8-Dibenzyl-2,2-dimethyl-6-oxo-7-[1-(2-trimethylsilanyl-ethoxymethyl)-1H-indazol-5-ylmethyl]-hexahydro-1,3-dioxa-5,7-diaza-azulen-5-ylmethyl}-benzoic acid 在 吡啶 、 四溴化碳 、 苯基锂 、 三苯基膦 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 生成 (3aS,4R,8R,8aS)-4,8-Dibenzyl-2,2-dimethyl-5-[3-(2-pyridin-2-yl-acetyl)-benzyl]-7-[1-(2-trimethylsilanyl-ethoxymethyl)-1H-indazol-5-ylmethyl]-hexahydro-1,3-dioxa-5,7-diaza-azulen-6-one
  参考文献：
  名称：

  Nonsymmetric P2/P2‘ Cyclic Urea HIV Protease Inhibitors. Structure−Activity Relationship, Bioavailability, and Resistance Profile of Monoindazole-Substituted P2 Analogues

  摘要：

  Using the structural information gathered from the X-ray structures of various cyclic urea/ HIVPR complexes, we designed and synthesized many nonsymmetrical P2/P2'-substituted cyclic urea analogues. Our efforts concentrated on using an indazole as one of the P2 substituents since this group imparted enzyme (K-i) potency as well as translation into excellent antiviral (IC90) potency. The second P2 substituent was used to adjust the physical and chemical properties in order to maximize oral bioavailability. Using this approach several very potent (IC90 11 nM) and orally bioavailable (F% 93-100%) compounds were discovered (21, 22). However, the resistance profiles of these compounds were inadequate, especially against the double (I84V/V82F) and ritonavir-selected mutant viruses. Further modification of the second P2 substituent in order to increase H-bonding interactions with the backbone atoms of residues Asp 29, Asp 30, and Gly 48 led to analogues with much better resistance profiles. However, these larger analogues were incompatible with the apparent molecular weight requirements for good oral bioavailability of the cyclic urea class of HIVPR inhibitors (MW < 610).

  DOI：

  10.1021/jm980103g
• 作为产物：
  描述：

  3-(溴甲基)苯甲酸甲酯 在 sodium hydroxide 、 potassium iodide 作用下， 以 1,4-二氧六环 、 乙腈 为溶剂， 反应 30.0h， 生成 3-{(3aS,4R,8R,8aS)-4,8-Dibenzyl-2,2-dimethyl-6-oxo-7-[1-(2-trimethylsilanyl-ethoxymethyl)-1H-indazol-5-ylmethyl]-hexahydro-1,3-dioxa-5,7-diaza-azulen-5-ylmethyl}-benzoic acid
  参考文献：
  名称：

  Nonsymmetric P2/P2‘ Cyclic Urea HIV Protease Inhibitors. Structure−Activity Relationship, Bioavailability, and Resistance Profile of Monoindazole-Substituted P2 Analogues

  摘要：

  Using the structural information gathered from the X-ray structures of various cyclic urea/ HIVPR complexes, we designed and synthesized many nonsymmetrical P2/P2'-substituted cyclic urea analogues. Our efforts concentrated on using an indazole as one of the P2 substituents since this group imparted enzyme (K-i) potency as well as translation into excellent antiviral (IC90) potency. The second P2 substituent was used to adjust the physical and chemical properties in order to maximize oral bioavailability. Using this approach several very potent (IC90 11 nM) and orally bioavailable (F% 93-100%) compounds were discovered (21, 22). However, the resistance profiles of these compounds were inadequate, especially against the double (I84V/V82F) and ritonavir-selected mutant viruses. Further modification of the second P2 substituent in order to increase H-bonding interactions with the backbone atoms of residues Asp 29, Asp 30, and Gly 48 led to analogues with much better resistance profiles. However, these larger analogues were incompatible with the apparent molecular weight requirements for good oral bioavailability of the cyclic urea class of HIVPR inhibitors (MW < 610).

  DOI：

  10.1021/jm980103g